ERG245
sodium 5-(4-bromophenyl)-5-oxo-4-phenyl-pentanoate
$200.00
ERG245 inhibits the cytosolic form of BCAT1, which catalyzes the reversible transfer of an amino group from a branched chain amino acid (leucine, isoleucine, valine) to an alpha-ketoglutarate molecule to generate glutamate. BCAT1 has functions in many immune and tumor cells.
Biological Activity: ERG245 inhibits BCAT1 enzymatic activity with an IC50 value of <0.5 nM in cell-free enzymatic assays and an IC50 value of >100 microM in cell-based enzymatic assays.
Properties: Yellowish solid, water soluble.
ERG245 is manufactured by Ergon Pharmaceuticals in USA and its structure is protected by US Patent 10,941,109.
ERG245 is supplied for Research Only and Not for Human Use. It is sold under the TSCA R&D Exemption (40 CFR Section 720.36). It is the recipient’s responsibility to comply with the requirements of the R&D exemption.
SDS and Product Datasheet are available upon request. Contact us at info@ergonpharma.com